Skip to main content
. Author manuscript; available in PMC: 2017 Nov 3.
Published in final edited form as: Prog Neuropsychopharmacol Biol Psychiatry. 2016 Aug 2;71:162–168. doi: 10.1016/j.pnpbp.2016.07.010

Table 1.

Participant characteristics by group (healthy controls [HC] or anxiety disorder [AD]) and specific diagnosis (generalized anxiety disorder [GAD] or social anxiety disorder [SAD])

HC (n = 35) AD (n = 28) SAD (n = 18) GAD (n = 20)

M(SD) % M(SD) % M(SD) % M(SD) %
Age 17.40 (3.26) 17.39(5.08) 18.78 (3.75) 17.00 (5.53)
Sex (% Female) 60.0% 67.9% 72.2% 80.0%
Site (% University of Michigan) 17.1% 25.0% 22.2% 25.0%
Treatment (% SSRI) - 57.1% 66.7% 45.0%
Comorbid GAD/SAD 0.0% 35.7% 55.6% 50.0%
Other comorbid anxiety 0.0% 25.0% 33.3% 30.0%
Comorbid depression 0.0% 14.3% 22.2% 10.0%
Number of sessions - 12.82(2.09) 12.06(0.87) 60.58(12.16)
Percent change in anxiety severity - 64.97(20.70) 60.58(12.16) 64.16(22.60)
ΔERN at Time 1 −5.73(4.66) −6.87(4.93) −9.09(4.29) −5.90(5.18)
ΔERN at Time 2 −7.53(4.11) −8.52(6.32) −10.79(6.33) −6.91(5.04)